158 related articles for article (PubMed ID: 16847824)
1. FDA perspective on trials with interim efficacy evaluations.
Temple R
Stat Med; 2006 Oct; 25(19):3245-9; discussion 3326-47. PubMed ID: 16847824
[TBL] [Abstract][Full Text] [Related]
2. Performance of adaptive sample size adjustment with respect to stopping criteria and time of interim analysis.
Jahn-Eimermacher A; Hommel G
Stat Med; 2007 Mar; 26(7):1450-61. PubMed ID: 16900553
[TBL] [Abstract][Full Text] [Related]
3. Adaptive methods: telling "the rest of the story".
Emerson SS; Fleming TR
J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
[TBL] [Abstract][Full Text] [Related]
4. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group.
Gallo P; Anderson K; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J
J Biopharm Stat; 2010 Nov; 20(6):1115-24. PubMed ID: 21058107
[TBL] [Abstract][Full Text] [Related]
5. Optimal spending functions for asymmetric group sequential designs.
Anderson KM
Biom J; 2007 Jun; 49(3):337-45. PubMed ID: 17623339
[TBL] [Abstract][Full Text] [Related]
6. Increasing the sample size when the unblinded interim result is promising.
Chen YH; DeMets DL; Lan KK
Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
[TBL] [Abstract][Full Text] [Related]
7. Stopping clinical trials early for benefit: impact on estimation.
Freidlin B; Korn EL
Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
[TBL] [Abstract][Full Text] [Related]
8. Adaptive, group sequential and decision theoretic approaches to sample size determination.
Mehta CR; Patel NR
Stat Med; 2006 Oct; 25(19):3250-69; discussion 3297-301, 3302-4, 3313-4, 3326-47. PubMed ID: 16927402
[TBL] [Abstract][Full Text] [Related]
9. FDA perspective on clinical trial design for cardiovascular devices.
Chen E; Sapirstein W; Ahn C; Swain J; Zuckerman B
Ann Thorac Surg; 2006 Sep; 82(3):773-5. PubMed ID: 16928481
[No Abstract] [Full Text] [Related]
10. Frequentist evaluation of group sequential clinical trial designs.
Emerson SS; Kittelson JM; Gillen DL
Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678
[TBL] [Abstract][Full Text] [Related]
11. A comparison of adaptive allocation rules for group-sequential binary response clinical trials.
Morgan CC; Stephen Coad D
Stat Med; 2007 Apr; 26(9):1937-54. PubMed ID: 16981177
[TBL] [Abstract][Full Text] [Related]
12. Accounting for interim safety monitoring of an adverse event upon termination of a clinical trial.
Dallas MJ
J Biopharm Stat; 2008; 18(4):631-8; discussion 439-45. PubMed ID: 18607795
[TBL] [Abstract][Full Text] [Related]
13. Sample size calculation for the Power Model for dose proportionality studies.
Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
[TBL] [Abstract][Full Text] [Related]
14. Sample size calculation in survival trials accounting for time-varying relationship between noncompliance and risk of outcome event.
Li B; Grambsch P
Clin Trials; 2006; 3(4):349-59. PubMed ID: 17060209
[TBL] [Abstract][Full Text] [Related]
15. Group sequential t-test for clinical trials with small sample sizes across stages.
Shao J; Feng H
Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814
[TBL] [Abstract][Full Text] [Related]
16. Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.
Gallo P; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J;
J Biopharm Stat; 2006 May; 16(3):275-83; discussion 285-91, 293-8, 311-2. PubMed ID: 16724485
[TBL] [Abstract][Full Text] [Related]
17. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.
Chuang-Stein C; Beltangady M
J Biopharm Stat; 2010 Nov; 20(6):1143-9. PubMed ID: 21058110
[TBL] [Abstract][Full Text] [Related]
18. Efficient group sequential designs when there are several effect sizes under consideration.
Jennison C; Turnbull BW
Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
[TBL] [Abstract][Full Text] [Related]
19. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences.
Schäfer H; Müller HH
Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350
[TBL] [Abstract][Full Text] [Related]
20. Re-estimating the sample size of an on-going blinded trial based on the method of randomization block sums.
Ganju J; Xing B
Stat Med; 2009 Jan; 28(1):24-38. PubMed ID: 18837073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
